BioXcel Therapeutics, Inc. (BTAIQ) vs IM Cannabis Corp. (IMCC)
BioXcel Therapeutics, Inc. and IM Cannabis Corp. are both Drug Manufacturers Specialty & Generic companies. BioXcel Therapeutics, Inc. is the larger, with a market value of $2.3M against $2.0M — 1.2× the size. IM Cannabis Corp. grew revenue faster over the last twelve months: −12.0% against −14.5%. IM Cannabis Corp. has the higher net margin (−38.9% vs −9,549.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, IM Cannabis Corp. leads on 11 and BioXcel Therapeutics, Inc. on 4.
Valuation
| Metric | BTAIQ | IMCC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| P/E | n/m | n/m | 20.14 |
| P/S | 1.63 | 0.03 | 2.25 |
| P/B | n/m | n/m | 1.90 |
| Price to free cash flow | n/m | n/m | 16.54 |
| EV/EBITDA | n/m | n/m | 12.29 |
| EV/Sales | 228.73 | 0.02 | 2.56 |
| Earnings yield | (9,475.00%) | (2,710.65%) | (2.99%) |
| Free cash flow yield | (4,201.65%) | (55.53%) | 0.00% |
Profitability
| Metric | BTAIQ | IMCC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 53.10% | 12.62% | 53.94% |
| Operating margin | (6,054.72%) | (32.88%) | 0.00% |
| Net margin | (9,549.87%) | (38.92%) | 0.00% |
| Free cash flow margin | (6,860.38%) | (1.47%) | 0.00% |
| Return on equity | 63.52% | 2,280.06% | (0.40%) |
| Return on assets | (259.62%) | (54.20%) | (3.32%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack